GAAP Net Income of $0.2 Million or $0.00 per Share; EBITDAR of $20.6 Million Revenue of $66.6 Million with Total Block Hours of 7,546 MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (Cboe CA: JET, Cboe CA: JET.B, OTCQB: JETMF) (the "Company" or "GlobalX"), the Nation's fastest growing charter airline, today announced its financial and operating results for the first quarter ended March 31, 2025. Except as otherwise disclosed, all figures for the three-month period are presented ...

Core Insights - Hudson Technologies, Inc. reported a revenue of $55.3 million for Q1 2025, a decrease of 15% compared to $65.3 million in Q1 2024, primarily due to lower refrigerant prices despite a slight increase in sales volume [9][16] - The gross margin for Q1 2025 was 22%, down from 33% in the same period last year, largely driven by price compression in the refrigerant market [9][16] - The company has a strong balance sheet with $81 million in cash and no debt as of March 31, 2025, and has repurchased $4.5 million of common stock in 2025 [4][8] Financial Performance - Revenues for Q1 2025 were $55.3 million, down 15% from $65.3 million in Q1 2024 [9][16] - Gross profit decreased to $12.1 million in Q1 2025 from $21.4 million in Q1 2024, reflecting the decline in gross margin [9][16] - Operating income fell to $3.1 million in Q1 2025 from $12.8 million in the prior year [9][16] - Net income for Q1 2025 was $2.8 million, or $0.06 per share, compared to $9.6 million, or $0.21 per share, in Q1 2024 [9][16] Market and Strategic Insights - The company anticipates continued growth in its reclamation business due to the phase-down of HFC refrigerants under the AIM Act, which is expected to reduce the supply of virgin HFCs [3] - Several states are implementing requirements for the use of reclaimed refrigerants in municipal buildings, creating additional demand opportunities [3] - Hudson Technologies is focused on responsible refrigerant management and has strengthened its capabilities through the acquisition of USA Refrigerants [2][3] Cash Flow and Capital Allocation - Cash provided by operating activities was $14.2 million in Q1 2025, compared to a cash used of $0.9 million in the same period last year [19] - The company invested $1.4 million in property, plant, and equipment during the quarter [20] - Hudson Technologies continues to pursue a capital allocation strategy that includes organic growth investments, acquisitions, and stock repurchases [4][8]

Three Months Ended March 31, 2025 Highlights AUSTIN, Texas, May 07, 2025 (GLOBE NEWSWIRE) -- Open Lending Corporation (Nasdaq: LPRO) (the "Company" or "Open Lending"), an industry trailblazer in lending enablement and risk analytics solutions for financial institutions, today reported financial results for its first quarter ended March 31, 2025. "I believe in Open Lending's business model, our value proposition to our customers, and the team's ability to execute on our plan going forward," said Jessica Buss ...

Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash runway anticipated to extend to post-launch positive operating cash flow Company to host a conference call today at 4:30 p.m. EDT SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" ...

NEW YORK and TOKYO, May 07, 2025 (GLOBE NEWSWIRE) -- HeartCore Enterprises, Inc. (Nasdaq: HTCR) ("HeartCore" or "the Company"), a leading enterprise software and data consulting services company based in Tokyo, will be virtually presenting and holding one-on-one meetings at the Sidoti Micro-Cap Conference on May 21-22, 2025. Headquartered in Tokyo, Japan, HeartCore Enterprises is a leading enterprise software and consulting services company. HeartCore offers Software as a Service (SaaS) solutions to enterpr ...

SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 1:40 p.m. P.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's website ...

Core Insights - ADMA Biologics reported a strong financial performance in Q1 2025, with total revenue of $114.8 million, representing a 40% year-over-year increase, and adjusted total revenue of $118.6 million, indicating approximately 45% growth when excluding one-time product withdrawals [1][9] - The company achieved a GAAP net income of $26.9 million, a 51% increase year-over-year, and an adjusted net income of $33.3 million, reflecting an 87% year-over-year growth [1][11] - Adjusted EBITDA for the quarter was $47.9 million, marking an 81% increase compared to the same period last year [1][12] Financial Performance - Total cash and receivables grew to approximately $171 million, providing a strong liquidity position [1][3] - The gross profit for Q1 2025 was $61.1 million, translating to a gross margin of 53.2%, up from 47.8% in Q1 2024 [10] - The company has increased its total revenue guidance for FY 2025 to more than $500 million and for FY 2026 to more than $625 million [1][7] Strategic Developments - The FDA approved a yield enhancement production process, expected to increase production output by 20% from the same starting plasma volume, which is anticipated to support revenue growth and margin expansion [1][3] - ADMA has authorized a $500 million share repurchase program, representing approximately 8% of its current market capitalization, aimed at enhancing stockholder value [1][8] - A debt reorganization has reduced ADMA's cost of debt capital by 1.1%, further strengthening its financial position [1][3] Market Position and Outlook - The company expects total annual revenues to exceed $1.1 billion by 2030, with significant earnings growth anticipated from current margin levels [2][7] - ADMA's U.S.-based manufacturing and supply chain provide insulation from geopolitical and global trade challenges, positioning the company favorably against multinational competitors [3][7] - The demand for ASCENIV, one of ADMA's key products, continues to trend towards record highs, with expectations for increased market penetration and new patient starts [4][7]

ROCKVILLE, MD, May 7, 2025 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell- engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2025 financial results and reiterated its 2025 guidance. First Quarter and Recent Highlights "MaxCyte has had a good start to 2025, with core revenue growth in the first quarter driven by continued strength ...

Reports 4.7% Sequential Quarter and 6.1% Annual Increase in NAV Reducing Leverage Net Deployments of $25.9 Million for the Fiscal Fourth Quarter 2025, Supporting One New Platform and Six Follow-Ons – Two Additional New Portfolio Companies Since Year-End Non-Accruals Reduced to 0.3% of Fair Value and 0.5% of Cost in Fiscal 2025 NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (NYSE: SAR) ("Saratoga Investment" or "the Company"), a business development company ("BDC"), today announced fina ...

- Beverage-grade Liquid CO2 Processor Acquisition and Corporate Reorganization Deliver Improved Year- over-Year Gross Margin and Adjusted EBITDA - PEKIN, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, reported its financial results for the quarter ended March 31, 2025. Bryon McGregor, President and Chief Executive Officer of Alto Ingredients said, "During the first quarter of 2 ...